Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder
Launched by SPROUT PHARMACEUTICALS, INC · Jan 25, 2008
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women with a primary diagnosis of HSDD who still needs to be treated according to the investigator's opinion and willing to continue in this study. This continuation requires adequate compliance, in the Investigators judgement, with trial medication and the trial visit required in the parent clinical trial (Visit 1 to visit 9).
- • Patients must have used a medically acceptable method of contraception \[i.e., double barrier method (e.g., diaphragm or condom and spermicide), hormonal therapy (subcutaneous, injectable, intra-vaginal, or oral contraceptive), intrauterine device, tubal sterilization, or partner's surgical sterilization\] for at least 3 months before the Screen Visit and continue to use that medically acceptable method of contraception during the trial.
- Exclusion Criteria:
- • Patients with a history of MDD within 6 months prior the Screen Visit or a score of 14 on the Beck Depression Inventory II, or a history of suicide attempt according to the Beck Scale for Suicide Ideation, or patient with any non-zero statement in the first five items for the Beck Scale for Suicide Ideation.
- • Patients must have a clinically acceptable Pap smear as read by a cytology facility (no evidence of malignancy or squamous intraepithelial lesions) within 6 months before the Inclusion Visit.
- • Patients with findings at the Screen Visit of pelvic inflammatory disease, urinary tract or vaginal infection/vaginitis, cervicitis, interstitial cystitis, vulvodynia, or significant vaginal atrophy.
- • Patients experiencing major life stress (including parenting pressure, eldercare, loss of income, death of a family member, etc.) or relationship discord that could interfere with sexual activity, except distress about HSDD.
- • Clinically significant ECG abnormalities at the Screen Visit, according to the investigators opinion or the cardiologist who have performed the ECG. The following ECG values are considered to be exclusionary: QTc intervals \>480 milliseconds (ms), PR intervals \>240 ms, and QRS intervals \>110 ms.
About Sprout Pharmaceuticals, Inc
Sprout Pharmaceuticals, Inc. is a leading biopharmaceutical company dedicated to advancing women's health by developing innovative therapies that address unmet medical needs. With a strong focus on scientific research and patient-centered solutions, Sprout is committed to improving the quality of life for women through the discovery and commercialization of safe and effective treatments. The company works collaboratively with healthcare professionals and regulatory bodies to ensure that its products meet the highest standards of safety and efficacy, ultimately empowering women to take control of their health and well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Innsbruck, , Austria
Wien, , Austria
Wien, , Austria
Wörgl, , Austria
Braine L'alleud, , Belgium
Edegem, , Belgium
Gent, , Belgium
Hasselt, , Belgium
Yvoir, , Belgium
Olomouc, , Czech Republic
Prague, , Czech Republic
Prague, , Czech Republic
Vresina, , Czech Republic
Espoo, , Finland
Helsinki, , Finland
Oulu, , Finland
Seinäjoki, , Finland
Tampere, , Finland
Blanquefort, , France
Bordeaux Cedex, , France
La Rochelle, , France
Lille, , France
Lille, , France
Marseille Cedex 9, , France
Marseille, , France
Marseille, , France
Rennes, , France
Saint Emilion, , France
Toulouse, , France
Berlin, , Germany
Bonn, , Germany
Dresden, , Germany
Frankfurt, , Germany
Freiburg, , Germany
Hannover, , Germany
Leipzig, , Germany
Budapest, , Hungary
Kecskemét, , Hungary
Szeged, , Hungary
Szentes, , Hungary
Catania, , Italy
Pavia, , Italy
Torino, , Italy
Almere, , Netherlands
Amsterdam, , Netherlands
Apeldoorn, , Netherlands
Bilthoven, , Netherlands
Den Helder, , Netherlands
Enschede, , Netherlands
Nieuwegein, , Netherlands
Barcelona, , Spain
Manresa (Barcelona), , Spain
Mataró Barcelona, , Spain
Orense, , Spain
Kungsbacka, , Sweden
Lund, , Sweden
Stockholm, , Sweden
Stockholm, , Sweden
Uppsala, , Sweden
Vasteras, , Sweden
Chorley, , United Kingdom
Fisherwick, Lichfield, , United Kingdom
Glasgow, , United Kingdom
Headington, Oxford, , United Kingdom
London, , United Kingdom
London, , United Kingdom
South Brent, , United Kingdom
Waterloo, Liverpool, , United Kingdom
Patients applied
Trial Officials
Sprout Pharmaceuticals
Study Chair
Sprout Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials